Expression of STAT6 and Phosphorylated STAT6 in Primary Central Nervous System Lymphomas.
CNS
Immune microenvironment
PD-L1
Prognosis
p-STAT6
Journal
Journal of neuropathology and experimental neurology
ISSN: 1554-6578
Titre abrégé: J Neuropathol Exp Neurol
Pays: England
ID NLM: 2985192R
Informations de publication
Date de publication:
27 09 2021
27 09 2021
Historique:
pubmed:
14
8
2021
medline:
30
12
2021
entrez:
13
8
2021
Statut:
ppublish
Résumé
The signal transducer and activator of transcription 6 (STAT6) is implicated in the pathogenesis of some lymphomas including primary central nervous system lymphomas (PCNSLs). The aim of this study was to investigate STAT6 expression and clinicopathologic features in 25 PCNSLs using immunohistochemistry with 2 different anti-STAT6 antibodies. One (YE361) recognizes the C-terminus domain of the STAT6 protein and the other (Y641) recognizes the phosphorylated form of the protein. The phosphorylated STAT6 form was not expressed in any of the cases studied whereas the YE361 STAT6 showed only cytoplasmic expression in 14 (56%) cases. This expression did not correlate with age, prognostic score, multiplicity, invasion of deep structures, response to treatment, disease recurrence, overall survival, or BCL6, BCL2, PD-L1, and CD8 expression. A STAT6 expression score showed a trend for correlating with clinical performance status. It also showed a positive correlation with MYC expression. Thus, the phosphorylated form of STAT6 was not found in the current series, while the YE361 STAT6 showed only cytoplasmic expression and was associated with expression of MYC.
Identifiants
pubmed: 34388250
pii: 6350867
doi: 10.1093/jnen/nlab080
doi:
Substances chimiques
STAT6 Transcription Factor
0
STAT6 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
830-834Subventions
Organisme : BRIF
ID : BB-0033-00041
Informations de copyright
© 2021 American Association of Neuropathologists, Inc. All rights reserved.